Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy.
Diego Salas-BenitoIñaki Eguren-SantamariaMiguel F SanmamedPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
It has been reported that a group of patients with advanced non-small cell lung cancer showed circulating T cells with a senescent phenotype, and an abundance of such cells is associated with worse clinical response to immune checkpoint inhibitors. This study encourages further analysis of the role of senescent T cells in resistance to lung cancer immunotherapy.See related article by Ferrara et al., p. 492.